CompoAtlas

Gelée royale Camomille Coquelicot

Food supplement declared in France, declaration No 2023-4-1219, decision dated 26 April 2023

Gelée royale Camomille Coquelicot (VITAVEA - Laboratoires Yves Ponroy) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Matricaria chamomilla 150 mg per day, Papaver rhoeas 100 mg per day, miel, Gelée royale. None of the rules we check flags an issue with its declared composition.

Brand
VITAVEA - Laboratoires Yves Ponroy
Food business operator placing the product on the market
HAVEA COMMERCIAL SERVICES
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Ampoule
Daily dose
1 ampoule
Directions for use
Pure ou diluée dans un verre d'eau le soir. Agitez avant emploi.
Objectives stated by the manufacturer (these are not authorised claims)
Sleep

Declaration 243005, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Matricaria chamomilla L.FleurExtrait sec aqueux150 mg
Papaver rhoeas L.PétalesExtrait sec aqueux100 mg

Other active ingredients

NamePer day
mielnot declared
Gelée royalenot declared

Other ingredients

eau, jus d'orange

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Ne pas dépasser la dose recommandée. A consommer dans le cadre d'une alimentation variée et équilibrée et d'un mode de vie sain. A garder hors de portée des enfants. A conserver dans un endroit sec et frais, à l'abri de la chaleur et de la lumière. Déconseillé aux personnes ayant un terrain allergique.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Matricaria chamomilla L.
    Read the warning, when it applies and the studies cited

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral

    Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).

    Cautions and warnings

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Health Canada monograph dated 19 December 2025

    German Chamomile - Matricaria Chamomilla Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 31 January 2025

    GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal

    Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)

    Cautions and warnings

    Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Health Canada monograph dated 29 May 2026

  • Gelée royale
    Read the warning, when it applies and the studies cited

    ROYAL JELLY

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Contraindications

    Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).

    Sources cited by Health Canada (8)
    • Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Case report
    • Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
    • Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
    • Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
    • Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
    • Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
    • TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
    • Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).

    Sources cited by Health Canada (6)
    • Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
    • Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
    • Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
    • Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
    • Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
    • Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report

    Health Canada monograph dated 24 April 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : VITAVEA - Laboratoires Yves Ponroy

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Gelée royale Camomille Coquelicot (VITAVEA - Laboratoires Yves Ponroy): composition and regulation”, https://compoatlas.com/en/supplements/products/243005-gelee-royale-camomille-coquelicot, updated 15 November 2026.

List recorded in 2023. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line